Skip to content

United Therapeutics UTHR Adcirca — Milestone payment to be made

Similar metrics at other companies

HRO
HROWAccrual Of Milestone Payment
$1.75M
OS Therapies logo
OSTXMilestone Payments
$22.38M0.0%
OS Therapies logo
OSTXMilestone Payments
$22.38M0.0%
CTO
CTORDevelopment Milestone Payments
$70M+155%
Insmed logo
INSMPayment Of Milestone
$15M
Celcuity logo
CELCOther Accrued License Milestone
$5M

Other financials

Income statement

See full
Revenue$781.5M-1.6%
Gross profit$648.1M-7.7%
Operating income$325.8M-14.9%
Net income$274.9M-14.7%
EPS (diluted)$5.82-12.2%

Balance sheet

See full
Cash & equivalents$1.3B-32.6%
Total debt$12.2M
Total equity$5.9B-13.3%
Total assets$6.7B-13.3%

Cash flow

See full
Operating cash flow$463.3M+0.5%
CapEx$100.8M+34.6%
Free cash flow$362.5M-6.2%

Valuation

See full
Market cap$23B+84.1%
P/E17.9×+7.8×
P/S7.3×+3.2×

Profitability

See full
Gross margin86.6%-2.4pp
Operating margin45.3%-1.6pp
Net margin40.6%+0.2pp
FCF margin32.1%-5.6pp

Returns & leverage

See full
Return on equity20.3%+0.3pp
Debt / equity
Current ratio4.8×-0.7×

Where this comes from

Reported directly by United Therapeutics in its filing.

Tagged under the XBRL concept uthr:MilestonePaymentToBeMadeUponCommercialLaunchOfProduct.

The official record: United Therapeutics’s 10-K, filed February 25, 2026, on SEC EDGAR. View the filing →

Ask your AI about United Therapeutics's adcirca — milestone payment to be made.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is United Therapeutics's adcirca — milestone payment to be made?
United Therapeutics (UTHR) reported adcirca — milestone payment to be made of $81.25K in Q4 2025.
How has United Therapeutics's adcirca — milestone payment to be made changed year-over-year?
United Therapeutics's adcirca — milestone payment to be made decreased by 0.0% year-over-year, from $81.25K to $81.25K.
What does adcirca — milestone payment to be made mean?
Reflects future financial obligations triggered by the achievement of specific development, regulatory, or commercial milestones for a product. These are non-recurring payments owed to partners or licensors upon reaching predefined targets.